Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Inclusion Criteria: Men or women age ≥18 years Histologically confirmed metastatic (stage IV) adenocarcinoma of the pancreas Measurable disease defined per RECIST Karnofsky Performance Status ≥50 Expected survival ≥12 weeks Provide written informed consent Exclusion Criteria: CNS metastases Prior treatment with other chemotherapy for pancreatic cancer unless used as a radiosensitizer Radiation therapy to >25% of the bone marrow Clinically significant laboratory abnormalities Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix The need for chronic (i.e., >7 days) oral or intravenous corticosteroid therapy with >10mg/day prednisone equivalents Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol Patients who are within 28 days of radiation therapy, biologic therapy, immunotherapy, or other investigational medication. All side effects of prior treatment must have resolved at study entry. Pregnancy or lactation